REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID ...
CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.
Nextcure ( ($NXTC) ) has released its Q3 earnings. Here is a breakdown of the information Nextcure presented to its investors. NextCure, Inc. is a ...
Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024. The decrease of $2.6 ...
The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.
21hon MSN
Nobel winner’s lab notches another breakthrough: AI-designed antibodies that hit their targets
Researchers from Nobel Laureate David Baker's lab at the University of Washington have successfully used AI to design ...
Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback